New Life Sciences and Biotechnology Center

New Life Sciences and Biotechnology Center Onyx Equities Announces New Jersey's Newest Life Sciences and Biotechnology Hub

The latest initiative, supported by leading real estate investment and services firm Onyx Equities and equity partner Machine Investment Group, is The Northeast Science and Technology (NEST) Center.

Onyx previously purchased this state-of-the-art campus, which served as Merck's global headquarters, in February 2023 with the future of life sciences and biotechnology in mind. Located just 14 miles outside New York City, NEST will serve as an industry innovation hub and attract next-generation life sciences and technology leaders to the region. John Saraceno, Founding Partner and Managing Partner of NEST Center, will participate in the BIO International Convention being held 5-8 June at the Boston Convention and Exhibition Center in Boston, Massachusetts, where he will share plans for the purposefully built research and development campus spanning more than 2 million square meters. Initial highlights include:

• 1.4 million square meters of laboratory building,
• 15 acres of redevelopment opportunities specifically dedicated for research, laboratories and manufacturing facilities,
• 500,000 square meters of Class A professional office space,
• Turnkey vivarium,
• Robust and redundant infrastructure including a 25 MW Combined Heat and Power Plant,
• State-of-the-art amenities including helipad, gymnasium, conference centers and green space to foster a vibrant campus culture.

Onyx Equities has a strong track record as a leading real estate owner and developer in the Northeast. NEST and other major life sciences projects in New Jersey continue to help position the company as one of the industry's new leaders. In fact, Johnson & Johnson's multibillion-dollar consumer company Kenvue recently selected an Onyx property to house its new global headquarters. Saraceno stated, "The biotechnology industry has strong demand for both turnkey and customizable solutions," and added, "Before NEST, many health technology companies, particularly those in research and development, had to wait years for adequate laboratory and working space. NEST allows those at the forefront of medicine to focus on finding cures rather than searching for office space." Saraceno noted that Onyx Equities chose to announce NEST at this year's BIO Convention in Boston because the event has a reputation for bringing together leaders, innovators and investors in the life sciences, biotechnology and medical device industries to celebrate the value that groundbreaking biotechnology brings to society. Source